Vaddi, Kris

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 2,103

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 1,497

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and Treatments

Cited by 843